Publicaciones en las que colabora con José Juan García Marín (18)

2024

  1. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

    Gut

  2. New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 5

  3. Non-mitogenic FGF19 mRNA-based therapy for the treatment of experimental metabolic dysfunction-associated steatotic liver disease (MASLD)

    Clinical science (London, England : 1979), Vol. 138, Núm. 20, pp. 1265-1284

2023

  1. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

2022

  1. New molecular mechanisms in cholangiocarcinoma: signals triggering interleukin-6 production in tumor cells and KRAS co-opted epigenetic mediators driving metabolic reprogramming

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  2. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models

    Journal of Hepatology, Vol. 77, Núm. 1, pp. 177-190

2021

  1. Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)

    British Journal of Cancer

  2. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

    Hepatology, Vol. 73, Núm. 6, pp. 2380-2396

2020

  1. Current and novel therapeutic opportunities for systemic therapy in biliary cancer

    British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059

  2. Dual pharmacological targeting of hdacs and pde5 inhibits liver disease progression in a mouse model of biliary inflammation and fibrosis

    Cancers, Vol. 12, Núm. 12, pp. 1-27

  3. Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: A machine-learning approach

    Cancers, Vol. 12, Núm. 6, pp. 1-30

2019

  1. The Epidermal Growth Factor Receptor Ligand Amphiregulin Protects From Cholestatic Liver Injury and Regulates Bile Acids Synthesis

    Hepatology, Vol. 69, Núm. 4, pp. 1632-1647

2018

  1. MicroRNA-506 promotes primary biliary cholangitis–like features in cholangiocytes and immune activation

    Hepatology, Vol. 67, Núm. 4, pp. 1420-1440

2017

  1. SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma

    Journal of Hepatology, Vol. 67, Núm. 1, pp. 72-83

2014

  1. Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases

    Gut, Vol. 63, Núm. 10, pp. 1658-1667

2013

  1. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice

    Gut, Vol. 62, Núm. 6, pp. 899-910

2012

  1. Lack of Abcc3 expression impairs bile-acid induced liver growth and delays hepatic regeneration after partial hepatectomy in mice

    Journal of Hepatology, Vol. 56, Núm. 2, pp. 367-373

  2. MicroRNAs in biliary diseases

    World Journal of Gastroenterology, Vol. 18, Núm. 43, pp. 6189-6196